VERBIO Vereinigte BioEnergie stock
VBK.DEXETRAVERBIO Vereinigte BioEnergie AG, Basic MaterialsISIN DE000A0JL9W6WKN A0JL9W
52Score 52 out of 100, Neutral
Price and trend
30 / 100
Price history
+42% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 20% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 33).
The price is 44% below its 52-week high. Largest decline in 20 years: 94% (March 2007 to December 2008).
Chart figures for advanced users
- SMA 50$31.52
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$35.29
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)33
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$17.76
- The lowest closing price of the last twelve months.
- Resistance$50.75
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- VERBIO Vereinigte BioEnergie AG belongs to the Chemicals (Specialty) industry (Germany) and, with a market value of $1.81B, is number 84 of 106 companies in its industry on MEQIRI.
- For fiscal 2027, analysts expect on average revenue of $2.28B (up 9.6%) and adjusted earnings per share of $2.20 (up 97.8%).
- MEQIRI Score 52 out of 100 (Neutral): rank 297 of 461 in Basic Materials, median 57.
Show more
- The P/E is 26.2 (Chemicals (Specialty) median 24.4, own median of recent years 17.7).
- Our model puts fair value at $46.99, with the price 40% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 40.1% a year through 2028 (estimates from 3 analysts).
- Below fair valuePrice 40% below the fair value of $46.99.Valuation 78
- Growing faster than its industryRevenue up 12.8% a year since 2021, Chemicals (Specialty) median 6%.
Weaknesses
- Volatile share priceVolatility 67% a year over the last 12 months.
- Margin fallingOperating margin 6.8%, average of the prior years 10.1% (to 2025).Profitability 36
Its standout strengths are valuation and stability, while profitability and technical analysis hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 53 to 52.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price far below its 52-week high
- cyclical sector (energy or materials), as a group, crashed more often in the backtest
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $31.33 and expensive above $93.98 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $67.57 (cash-flow model) and $26.41 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $41.16, at 6.1% it would be $55.74.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (24.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue rose 18.5% on the prior year. Revenue has grown solidly since 2008, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 18%, operating 7%, net 3%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 11 Feb 2027in 90 days
- Last reported
- 24 Sep 2026EPS reported $0.72 (expected $0.97)below expectations
Analyst estimates
Analysts have raised their 2028 earnings estimate by 5.5% since 15 Oct 2026.
- Earnings per share
- $2.20+0.5%
- Revenue
- $2.28B+2.5%
- Earnings per share
- $2.88+5.5%
- Revenue
- $2.54B+1.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.5%First outlook for 2026/27: group EBITDA expected to increase to EUR 210 million to EUR 250 million, with capital expenditure declining further.
“We expect group EBITDA to increase to between EUR 210 million and EUR 250 million, driven by the Bioethanol and Biomethane segment.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 24 Sep 2026 (fiscal Q4 2026), read by AI.
What happened at VERBIO Vereinigte BioEnergie
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
461 rated companies in Basic Materials
- This company
- 52
- Sector median
- 57
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- IngevityNGVT $2.09B60
- ChemoursCC $2.01B32
- InnospecIOSP $1.95B64
- Minerals TechnologiesMTX $1.92B45
- CorbionCRBN.AS $1.7B66
- BorregaardBRG.OL $1.64B63
- Stepan CoSCL $1.51B51
- Industrie De NoraDNR.MI $1.32B45
ETFs that hold VERBIO Vereinigte BioEnergie
Held by 22 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi SDAX UCITS ETF DistC005 | 1.22% | 0.70% | €158.8M |
| Invesco Global Clean Energy UCITS ETF AccumUSDG1CE | 0.88% | 0.60% | €88.94M |
| Amundi Global Bioenergy UCITS ETF EUR AccWDNR | 0.43% | 0.35% | €146.72M |
Show 5 more
| iShares TecDAX UCITS ETF (DE)EXIB | 0.36% | 0.51% | €12.44M |
| iShares Global Clean Energy Transition UCITS ETFIQQH | 0.26% | 0.65% | €2.52B |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.12% | 0.40% | €580.62M |
| UBS MSCI EMU Small Cap UCITS ETF EUR disUEFD | 0.09% | 0.28% | €630.46M |
| Amundi F.A.Z. 100 UCITS ETFC006 | 0.06% | 0.15% | €104.39M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 17 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.